Artelo Biosciences, Inc. (ARTL) NASDAQ

1.05

+0.035(+3.45%)

Updated at May 30 04:00PM

Currency In USD

Artelo Biosciences, Inc.

Address

505 Lomas Santa Fe

Solana Beach, CA 92075

United States of America

Phone

858 925 7049

Sector

Healthcare

Industry

Biotechnology

Employees

6

First IPO Date

June 21, 2019

Key Executives

NameTitlePayYear Born
Mr. Gregory D. Gorgas M.B.A.President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary & Director820,4541963
Dr. Steven D. Reich M.D.Chief Medical Officer01946
Mr. Jason H. BaybuttSenior Vice President of Finance01972
Dr. Andrew Yates Ph.D.Senior Vice President & Chief Scientific Officer0N/A

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.